1-3 of 3
Jean-Michel Miclea
Close
Sort by
Journal Articles

Identification Of Patients (pts) With Chronic Myeloid Leukemia (CML) At High Risk Of Artery Occlusive Events (AOE) During Treatment With The 2 nd Generation Tyrosine Kinase Inhibitor (TKI) Nilotinib, Using Risk Stratification For Cardiovascular Diseases (CVD)

Delphine Rea, MD, PhD, Tristan Mirault, MD, Emmanuel Raffoux, MD, Jean-Michel Miclea, MD, Philippe Rousselot, Herve Dombret, M.D., Emmanuel Messas, MD
Journal: Blood
Blood (2013) 122 (21): 2726.
https://doi.org/10.1182/blood.V122.21.2726.2726
Published: 2013
Journal Articles

Autologous Hematopoietic Stem Cell Collection and Transplantation in Acute Myeloid Leukemia Patients in Second Remission after Treatment with Fractionated Gentuzumab Ozogamycin.

Delphine Rea, MD, PhD, Emmanuel Raffoux, MD, Anne Laure Taksin, MD, Adrienne De Labarthe, MD, Nicolas Boissel, MD, Jean Michel Miclea, MD, Sylvie Castaigne, MD, Herve Dombret, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 5211.
https://doi.org/10.1182/blood.V108.11.5211.5211
Published: 2006
Journal Articles

Assessment of PML-RARa Real-Time Quantitative PCR for Definition of Molecular Relapse in APL Patients (Results of the APL Study Group).

Bruno Cassinat, Stephane De Botton, Lionel Ades, Emmanuel Raffoux, Martine Escoffre-Barbe, Andre Baruchel, Jean-Michel Miclea, Oumedaly Reman, Martine Gardembas, Philippe Brault, Noel Milpied, Olivier Legrand, Herve Dombret, Pierre Fenaux, Christine Chomienne
Journal: Blood
Blood (2005) 106 (11): 672.
https://doi.org/10.1182/blood.V106.11.672.672
Published: 2005